Xencor Inc (XNCR) - Total Liabilities
Based on the latest financial reports, Xencor Inc (XNCR) has total liabilities worth $243.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Xencor Inc to assess how effectively this company generates cash.
Xencor Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Xencor Inc's total liabilities have evolved over time, based on quarterly financial data. Check XNCR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Xencor Inc Competitors by Total Liabilities
The table below lists competitors of Xencor Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
China | CN¥412.55 Million |
|
Synsam AB
ST:SYNSAM
|
Sweden | Skr5.83 Billion |
|
Abacus Life Inc.
NASDAQ:ABL
|
USA | $479.34 Million |
|
Campus Activewear Limited
NSE:CAMPUS
|
India | Rs7.38 Billion |
|
Troilus Gold Corp
TO:TLG
|
Canada | CA$11.76 Million |
|
Zhejiang Langdi Group Co Ltd
SHG:603726
|
China | CN¥1.39 Billion |
|
Jiangsu Flowers King
SHG:603007
|
China | CN¥1.26 Billion |
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
Korea | ₩739.61 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Xencor Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Xencor Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xencor Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xencor Inc (2011–2024)
The table below shows the annual total liabilities of Xencor Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $277.92 Million | -1.99% |
| 2023-12-31 | $283.56 Million | +138.75% |
| 2022-12-31 | $118.77 Million | +13.43% |
| 2021-12-31 | $104.71 Million | -19.95% |
| 2020-12-31 | $130.80 Million | +69.76% |
| 2019-12-31 | $77.05 Million | +39.96% |
| 2018-12-31 | $55.05 Million | -49.05% |
| 2017-12-31 | $108.06 Million | -5.72% |
| 2016-12-31 | $114.61 Million | +157.68% |
| 2015-12-31 | $44.48 Million | +421.25% |
| 2014-12-31 | $8.53 Million | -38.08% |
| 2013-12-31 | $13.78 Million | -55.77% |
| 2012-12-31 | $31.16 Million | -6.45% |
| 2011-12-31 | $33.31 Million | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more